Clinical and morphological analysis of inflammatory breast cancer
Abstract
We analyzed the primary medical documentation of 192 patients with the established in 2009-2013 diagnosis "breast cancer stage cT4N0-3M0". There were statistically significant differences in overall and progression-free survival depending on both the degree of involved regional lymph nodes (cN0-2 vs cN3) and the use of surgery and radiotherapy (p < 0.05). Statistically significant differences in progression-free (p = 0.022), but not in overall survival (p = 0.971) according to use/no use of neoadjuvant chemotherapy were identified. The objective response to neoadjuvant chemotherapy with the inclusion of anthracycline was influenced by the hormone-receptor status, as well as by the molecular genetic subtype (p < 0.05), but not by the histologic characteristics of the tumor (p > 0.05).
About the Authors
I. Y. Tratsiak
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
Y. E. Demidchik
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
S. A. Kostiuk
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
References
1. TNM classification of malignant tumors / L. Sobin [et al.]. - New York, 2002. - P. 336.
2. Портной, С. М. Лечение местнораспространенного рака молочной железы / С. М. Портной // Сибир. онкол. журн. - 2008. - Прил. № 2. - С. 14-22.
3. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) Program / P. H. Levine [et al.] // J. Natl. Cancer Inst. - 1985. - Vol. 74. - P. 291-297.
4. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975-1992 / S. Chang [et al.] // Cancer. - 1998. - Vol. 82. - P. 2366-2372.
5. Jaiyesimi, I. A. Inflammatory breast cancer: a review / I. A. Jaiyesimi, A. U. Buzdar, G. Hortobagyi // J. Clin. Oncol. -1992. - Vol. 10. - P. 1014-1024.
6. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy / J. Rouesse [et al.] // J. Clin. Oncol. - 1986. - Vol. 4. - P. 1765-1771.
7. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience / A. U. Buzdar [et al.] // Surg. Oncol. Clin. - 1995. - Vol. 4. - P. 715-734.
8. Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results program at the National Cancer Institute / K. W. Hance [et al.] // J. Natl. Cancer Inst. - 2005. - Vol. 97. - P. 966-975.
9. Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy / J. A. Low [et al.] // J. Clin. Oncol. - 2004. - Vol. 22. - P. 4067-4074.
10. Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast / J. C. Delarue [et al.] // Br. J. Cancer. - 1981. - Vol. 44. - P. 911-991.
11. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease / A. Paradiso [et al.] // Cancer. - 1989. - Vol. 64. - P. 1922-1927.
12. Lerebours, F. Update on inflammatory breast cancer / F. Lerebours, I. Bieche, R. Lidereau // Breast Cancer Res. -2005. - Vol. 7, N 2. - P. 52-58.
13. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience / S. A. Aziz [et al.] // Breast J. - 2001. - Vol. 7. - P. 398-404.
14. Giordano, S. H. Inflammatory breast cancer: clinical progress and the main problems that must be addressed / S. H. Giordano, G. N. Hortobagyi // Breast Cancer Res. - 2003. - Vol. 5, N 6. - P. 284-288.
15. Multimodality therapy in inflammatory breast cancer: is there a place for surgery? / R. H. De Boer [et al.] // Ann. Oncol. - 2000. - Vol. 11, N 9. - P. 1147-1153.
16. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma / R. Y. Fleming [et al.] // Ann. Surg. Oncol. - 1997. - Vol. 4. - P. 452-461.
17. Hagelberg, R. S. Role of surgery in the treatment of inflammatory breast carcinoma / R. S. Hagelberg, P. C. Jolly, R. P. Anderson // Am. J. Surg. - 1984. - Vol. 148. - P. 125-131.
18. Ten-year outcome after combined modality therapy for inflammatory breast cancer / E. E. R. Harris [et al.] // Int. J. Radiat. Oncol. Biol. Phys. - 2003. - Vol. 55. - P. 1200-1208.
19. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma / C. A. Perez [et al.] // Cancer. - 1994. - Vol. 74. - P. 466-476.
20. Sinclair, S. Primary systemic chemotherapy for inflammatory breast cancer / S. Sinclair, S. M. Swain // Cancer. -2010. - Vol. 116, N 11. - P. 2821-2828.
21. Kell, M. R. Surgical aspects of inflammatory breast cancer / M. R. Kell, M. Morrow // Breast Dis. - 2005. - Vol. 22. - P. 67-73.
22. Inflammatory breast cancer: the disease, the biology, the treatment / F. M. Robertson [et al.] // CA Cancer J. Clin. -2010. - Vol. 60, N 6. - P. 351-375.
23. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Updates. 2013. Version 2 NCCN guidelines. Available at: http://www.nccn.org/. 2009.
24. Long-term results of combined-modality therapy for inflammatory breast carcinoma / E. Baldini [et al.] // Clin. Breast Cancer. - 2004. - Vol. 5, N 5. - P. 358-363.
25. High incidence of HER-2 positivity in inflammatory breast cancer / M. Parton [et al.] // Breast. - 2004. - Vol. 13, N 2. - P. 97-103.
26. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer / M. Sawaki [et al.] // Breast Cancer. - 2006. - Vol. 13, N 2. - P. 172-178.
27. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer / E. Turpin [et al.] // Oncogene. - 2002. - Vol. 21, N 49. - P. 7593-7597.
28. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 / D. J. Slamon [et al.] // Science. - 1987. - Vol. 235. - P. 177-182.
29. Полиморфизм генов глутатион^-трансфераз и результаты химиотерапии рака яичников / А. А. Моисеев [и др.] // Вестн. рос. онкол. науч. центра имени Н. Н. Блохина РАМН. - 2008. - Т. 19, № 1. - С. 59-64.
30. Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy / R. L. Bauer [et al.] // Ann. Surg. Oncol. - 1995. - Vol. 2, N 4. - P. 288-294.
31. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1,1) / E. A. Eisenhauer [et al.] // Eur. J. of Cancer. - 2009. - Vol. 45. - P. 228-247.
Review
For citations:
Tratsiak I.Y., Demidchik Y.E., Kostiuk S.A. Clinical and morphological analysis of inflammatory breast cancer. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2016;(1):4-10. (In Russ.)
Views: 715
Email this article 